3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
65
Neoplasms
56
Prostatic Neoplasms
44
Lung Neoplasms
35
Colorectal Neoplasms
35
Carcinoma, Non-Small-Cell Lung
24
Pancreatic Neoplasms
21
Hematologic Neoplasms
19
Head and Neck Neoplasms
16
Neoplasm Metastasis
15
Urinary Bladder Neoplasms
12
Ovarian Neoplasms
11
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Motor Activity
10
Triple Negative Breast Neoplasms
9
Multiple Myeloma
9
Colonic Neoplasms
9
Melanoma
8
Glioma
8
Anxiety Disorders
8
Uterine Cervical Neoplasms
7
Hematopoietic and Lymphatic System Neoplasm
7
Glioblastoma
7
Gastrointestinal Neoplasms
7
Esophageal Neoplasms
7
Anatomic Stage I Breast Cancer AJCC v8
7
Smoking Cessation
6
Sarcoma
6
Rectal Neoplasms
6
Interventions
Cyclophosphamide
9
Temozolomide
7
Radiotherapy
6
Magnetic Resonance Spectroscopy
5
Filgrastim
5
Cisplatin
5
Carboplatin
5
antineoplaston AS 2-1
4
antineoplaston A10
4
Etoposide
4
sargramostim
3
Vincristine
3
Thiotepa
3
Melphalan
3
Automobiles
3
fludarabine
2
aldesleukin
2
Thalidomide
2
Surveys and Questionnaires
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Gadolinium DTPA
2
Eflornithine
2
Donepezil
2
Carmustine
2
Biopsy
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
trifluridine tipiracil drug combination
1
trametinib
1
thymoglobulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroectodermal Tumors, Primitive
×
Standard of Care
×
Clear all
NCT06861244
2026-04-23
PNOC031
University of California, San Francisco
Phase 2
Recruiting
70 enrolled